Clinical Trials Logo
  1. Home
  2. Lung Neoplasms
  3. NCT03171636

Frequency of EGFR and KRAS Mutations and Clinical-prognostic Correlation in Brazilian Lung Cancer Patients

Lung Neoplasms Clinical Trial

Official title:
Analysis of the Types and Frequency of EGFR and KRAS Mutations and Clinical-prognostic Correlation in Brazilian Lung Cancer Patients at Erasto Gaertner Hospital, Curitiba, Brazil.

Clinical Trial Summary

The assessment of the type and frequency of EGFR and KRAS mutations in lung cancer patients, as well as clinical-prognostic correlation, are crucial in the era of targeted therapies. EGFR-activating mutations predict responsiveness to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) patients and KRAS analysis will be useful in a near future for newest target drugs. In Brazil, few data about the prevalence of EGFR and KRAS mutations is available and their knowledge would allow optimize personalized medicine.

Clinical Trial Description

Assessment of the types and frequency of EGFR and KRAS mutations in NSCLC, as well clinical-prognostic correlations has been extensively studied in many populations. Few Brazilian studies evaluating mutational status in NSCLC has been done so far, none of then explored the regional background nor have considered the quantitative analysis of mutant cell in each sample. Quantitative analysis of the tumor maybe relevant for treatment design for positive samples, p.e a tumor with 90% of mutant clones versus a 15% of mutant clones, which can be obtained currently by the method of pyrosequencing. In this study, investigators will assess EGFR and KRAS status through the pyrosequencing quantitative technique, and will also correlate these with clinical-pathological variables among both adenocarcinoma and squamous cell histological subtypes. So far, no study that have made this correlation is available. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03171636
Study type Observational
Source Hospital Erasto Gaertner
Contact
Status Completed
Phase
Start date April 2014
Completion date January 2019
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03357094 - Pulmonary Ventilation/Perfusion Imaging for the Prediction of Postoperative Residual Pulmonary Function N/A
Recruiting NCT05543954 - 68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients Early Phase 1
Completed NCT01114958 - Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases Phase 1
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Not yet recruiting NCT02907606 - Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study N/A
Completed NCT02926768 - Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors Phase 1
Active, not recruiting NCT02514512 - Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking N/A
Completed NCT02531737 - Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer Phase 2
Completed NCT02334007 - Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery Phase 1/Phase 2
Active, not recruiting NCT02284633 - Blood Sample Monitoring of Patients With EGFR Mutated Lung Cancer
Completed NCT02106143 - RejuvenAir™ System Lobectomy Safety and Histology Study N/A
Completed NCT01933789 - Improving Communication About Serious Illness N/A
Enrolling by invitation NCT01687647 - Sputum Cytometry Analysis in Lung Cancer Screening After Professional Asbestos Exposure Phase 3
Completed NCT00385177 - Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors Phase 1
Terminated NCT00356525 - Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor Phase 2
Completed NCT00243685 - Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis Phase 2/Phase 3
Completed NCT00351962 - Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable NSCLC or Metastatic Lung Tumours N/A
Completed NCT00129844 - Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer Phase 2
Withdrawn NCT00090701 - A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer Phase 2
Recruiting NCT01789229 - Establishment of a Tumor Bank for Tissue Samples